Compare NUAI & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUAI | AURA |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 633.1M | 713.4M |
| IPO Year | N/A | 2021 |
| Metric | NUAI | AURA |
|---|---|---|
| Price | $4.40 | $6.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $11.00 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 9.5M | 749.6K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $4.73 |
| 52 Week High | $9.45 | $9.54 |
| Indicator | NUAI | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 39.66 | 47.57 |
| Support Level | $3.71 | $6.34 |
| Resistance Level | $5.31 | $7.04 |
| Average True Range (ATR) | 0.70 | 0.56 |
| MACD | -0.21 | 0.03 |
| Stochastic Oscillator | 6.85 | 28.08 |
New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.